Efficacy And Safety Profile of Erythropoietin in Chronic Kidney Disease Patients of Vizianagaram, Andhra Pradesh

Authors

  • Sindhura Nagisetty Assistant Professor, Department of Pharmacology, GITAM Institute of Medical Sciences and Research, Visakhapatnam, Andhra Pradesh, India
  • Naga Sreenivasulu Jillella Assistant Professor, Department of General Medicine, GITAM Institute of Medical Sciences and Research, Visakhapatnam, Andhra Pradesh, India
  • Tulasi Madhuri Thotakura Associate Professor, Department of Pharmacology, GITAM Institute of Medical Sciences and Research, Visakhapatnam, Andhra Pradesh, India
  • Madhav P Associate Professor, Department of Pharmacology, Apollo Institute of Medical Sciences and Research, Chittoor, Andhra Pradesh, India

Keywords:

Erythropoietin, Anaemia, Chronic Kidney Disease, Haemoglobin.

Abstract

Background: Anaemia is a common complication of chronic kidney disease. The close relationship between haematopoiesis and the kidney was first recognized by Richard Bright in 1835 when he described the association between anaemia and chronic renal failure. Much of the morbidity in renal failure patients can be attributed to the consequences of their chronic anaemia. Aim & Objectives: The aim of this study is to evaluate the efficacy and safety of human recombinant Erythropoietin in the treatment of anaemic patients due to chronic renal failure. Methods: This study was conducted at Department of Nephrology and dialysis unit, MIMS, Vizianagaram. Study Period was from October 2013 to September 2015 who are on haemodialysis for duration of six months to two years. For this a total number of 46 participants were screened. All 46 patients were given erythropoietin [EPOFIT] manufactured by INTAS pharmaceuticals by subcutaneous route Results: Patients will undergo laboratory investigations for haemoglobin, haematocrit (Hct), reticulocytes, RBC counts, serum ferritin and TSAT at the baseline and end of the study. Haemoglobin, haematocrit and red cell count, reticulocytes, serum ferritin and TSAT will be done once in 4 weeks till the end of the study. Conclusion: Of the total 46 patients enrolled in the study, 31 patients required only regular conventional dose of 50 units /kg /dose and only 9 patients required incremental dose of erythropoietin 75 units/kg to achieve target haemoglobin level. In our study Haemoglobin increased progressively in 77% patients at 4 weeks and 23% patients at the end of 12 weeks.

Downloads

Published

2022-01-18

How to Cite

Sindhura Nagisetty, Naga Sreenivasulu Jillella, Tulasi Madhuri Thotakura, & Madhav P. (2022). Efficacy And Safety Profile of Erythropoietin in Chronic Kidney Disease Patients of Vizianagaram, Andhra Pradesh. International Journal of Health and Clinical Research, 5(3), 209–212. Retrieved from https://www.ijhcr.com/index.php/ijhcr/article/view/4348